Keely Macmillan, MSPH
Advertisement
Articles by Keely Macmillan, MSPH
COVID-19 has delayed the transition to Oncology Care First, but the forthcoming model could help.
Oncology drug costs affect those entering into risk-based arrangements, and these groups must rethink their approach to evaluating risk.
Advertisement
Latest Updated Articles
Biosimilars Drive Savings in Medicare’s Oncology Care ModelPublished: June 19th 2021 | Updated:
Three Ways COVID-19 Makes the Oncology Care First Model More AttractivePublished: October 29th 2020 | Updated:
- Rethinking Downside Risk Protection Amid Growth in Precision Medicine
Published: August 16th 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
ICE Presence in Minnesota Health Care Settings Threatens Access to Essential Medical Care
2
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
3
Experts Warn CDC Childhood Immunization Schedule Revisions Could Reduce Uptake, Erode Public Trust
4
CMS Proposes Nearly Flat 2027 Medicare Advantage Payment Rates
5
